Contents
We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases.
Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.
Timeline
No Timeline data yet.
Funding Rounds
Open in Query Tool
Products
Open in Query Tool
Acquisitions
Open in Query Tool
SBIR/STTR Awards
Open in Query Tool
Patents
Open in Query Tool
Further Resources
Title
Author
Link
Type
Date
No Further Resources data yet.
References
Company attributes
B2X
-1
Pitchbook URL
Number of Employees (Ranges)
1 – 10-1
Full Address
29 rue du faubourg saint jacques, PARIS, FR
Investors
Founded Date
2014
Email Address
bd@coavetx.com
contact@coavetx.com
Total Funding Amount (USD)
38,900,000
Latest Funding Round Date
July 21, 2021
Latest Funding Type
Patents Assigned (Count)
1
Other attributes
Company Operating Status
Active
Latest Funding Round Amount (USD)
38,900,000
